Pseudohypoparathyroidism is a rare, deeply impairing disorder of calcium metabolism. Identifying PHP-Ia patients before development of hypocalcemia is prudent to prevent hypocalcemia-related complications, such as generalized tetany and seizure. Meticulous clinical examination for AHO phenotype helps in early diagnosis and treatment of this disorder.
Learning points for clinicians
Pseudohypoparathyroidism is a rare, deeply impairing disorder of calcium metabolism. Identifying PHP-Ia patients before development of hypocalcemia is prudent to prevent hypocalcemia-related complications, such as generalized tetany and seizure. Meticulous clinical examination for AHO phenotype helps in early diagnosis and treatment of this disorder.
Case presentation
An 18-year-old girl presented to outpatient department with complaints of recurrent episodes of hand spasm and facial twitching for 1 month. Her general physical examination revealed height of 145 cm (<3rd centile), round face, stocky physique and bradymetacarpia of fourth and fifth fingers bilaterally. Signs of latent tetany in the form of Chvostek's and Trousseau's sign were present. She had no cognitive defects. Radiography of hands showed fourth and fifth metacarpal shortening, along with osteodystrophic features ( Figure 1A) , suggestive of Albright's hereditary osteodystrophy. Computed tomography of brain revealed multiple calcifications in basal ganglia, caudate nucleus, frontal region and parietal lobes ( Figure 1B ). Blood investigations revealed low serum calcium (1.7 mmol/l) with high serum phosphate (2.1 mmol/l). Serum parathyroid hormone levels were markedly elevated (331 ng/l) with normal 25 (OH) vitamin D levels (78.4 nmol/l). Patient was diagnosed as Pseudohypoparathyroidism type 1a, and started on calcitriol and calcium supplementation. She responded to the treatment, and is presently asymptomatic with maintenance of near-normal calcium levels. She also had oligomenorrhea. Serum gonadotropins, prolactin and ultrasound pelvis were normal. Thyroid profile revealed normal T3, T4 levels with slightly elevated TSH levels (TSH-9.5lIU/l), suggestive of TSH resistance. Goiter and thyroid peroxidase antibodies were absent. Patient was supplemented with levothyroxine for the same.
Discussion
Pseudohypoparathyroidism (PHP) is historically the first hormone resistance syndrome, described in 1952 by Fuller Albright. It encompasses a heterogeneous group of rare metabolic disorders, all characterized by end-organ resistance to the action of parathyroid hormone (PTH). Pseudohypoparathyroidism type 1 (PHP-I) is characterized by PTH resistance (elevated PTH levels in the presence of hypocalcemia and hyperphosphatemia), associated with a blunted cAMP and phosphaturic response to exogenous PTH. Resistance to PTH generally develops over the first years of life, with hyperphosphatemia and elevated PTH usually preceding hypocalcemia. PHP patients are not prone to hypercalciuria, as resistance to PTH occurs only in the proximal tubule without affecting the thick ascending limb. The disorder is caused by a maternally transmitted mutation in the gene encoding adenylate cyclase stimulating G alpha protein (GNAS1). gonadotropins manifests as delayed or incomplete sexual maturation, amenorrhea or oligomenorrhoea and/or infertility. PHP-I patients should be monitored annually for both blood biochemical profile (PTH, calcium, phosphate, TSH) and urinary calcium excretion. Active vitamin D metabolites, preferentially calcitriol, with or without oral calcium supplementation, are the treatment of choice, and the dose should be titrated to maintain normocalcemia. 2 Patients with PHP-I should also be screened and treated for associated endocrinopathies, particularly hypothyroidism and hypogonadism.
Conclusion
Pseudohypoparathyroidism includes a heterogeneous group of rare metabolic disorders, characterized by end-organ resistance to the action of parathyroid hormone. It should be kept in the differential diagnosis of hypocalcemia with hyperphosphatemia.
Meticulous examination for phenotype of AHO aids in early diagnosis and treatment of this disorder.
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